Drug Safety Problems Show Potential For Follow-On Biologics, Jaeger Says
This article was originally published in The Pink Sheet Daily
Executive Summary
GPhA President Jaeger argues that improved analytics developed in the wake of the heparin problems suggest that non-clinical verification of follow-on products is possible.